Biotechnological Innovations to Combat Antimicrobial Resistance and Advance Global Health Equity

Simple item page
dc.contributor.authorRugarabamu, Sima.
dc.contributor.authorMwanyika, Gaspary.
dc.date.accessioned2025-11-07T08:58:44Z
dc.date.available2025-11-07T08:58:44Z
dc.date.issued2025-09-05
dc.descriptionThis Journal Article was Published by MDPI
dc.description.abstractAntimicrobial resistance (AMR) is a growing global health emergency that threatens the effectiveness of modern medicine, exacerbating healthcare costs, morbidity, and mortal- ity, particularly in low- and middle-income countries (LMICs). Traditional approaches to antimicrobial development and stewardship have proven inadequate in curbing the rapid emergence and spread of resistant pathogens. This review explores cutting-edge biotechnological innovations as sustainable, precision-based solutions to combat AMR and promote global health equity. A comprehensive narrative review was conducted using literature published between 2018 and 2023 from PubMed, ScienceDirect, and Web of Science. Peer-reviewed studies focusing on novel antimicrobial strategies were the- matically analyzed, with attention to efficacy, feasibility, and translational readiness. Key innovations identified include nanotechnology-enhanced antimicrobial delivery, bacterio- phage therapy, CRISPR-Cas gene editing, immunotherapy, and personalized medicine. These strategies demonstrated substantial in vitro and in vivo efficacy, such as >90% MRSA biofilm reduction via silver nanoparticles and 95% carbapenem susceptibility restoration in E. coli using CRISPR-Cas9. When integrated with machine learning and rapid diagnos- tics, these approaches enable precision-targeted therapies and data-informed stewardship, offering scalable solutions adaptable to diverse healthcare systems. Antimicrobial resis- tance demands urgent, equitable innovation. Integrating biotechnologies like CRISPR, phage therapy, and nanomedicine with data-driven tools offers promising solutions. To ensure real-world impact, we recommend establishing regionally tailored translational research platforms and public–private partnerships as the most effective strategy to scale innovations and strengthen AMR response in low-resource settings.
dc.description.sponsorshipPrivate
dc.identifier.urihttps://repository.must.ac.tz/handle/123456789/511
dc.language.isoen
dc.publisherMDPI
dc.titleBiotechnological Innovations to Combat Antimicrobial Resistance and Advance Global Health Equity
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
bacteria-04-00046 (1)-compressed.pdf
Size:
237.71 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Journal Articles